Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Phase 3

• Conditions: Human Papilloma Virus

• Registration Number: NCT02382900
• Lead Sponsor: Universidad Nacional Autonoma de Mexico

Brief Summary

In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease. The HPV 16 and 18 are the most common oncogenic "high-risk" genotypes and cause approximately 70% of all cervical cancers despite the fact that are associated with other anogenital cancers, anus, vagina, vulva and penis, and cancers of the head and neck. Current estimates are that 5.2% of all cancers are HPV associated. A large number of studies, including both adult and young females, have demonstrated that HPV vaccines are highly immunogenic and induce a long lasting protection against infection. Immunogenic vaccination results in young men and boys are equally satisfactory with the quadrivalent HPV (types 6, 11, 16, 18) vaccine recommended for men. The recommended vaccination scheme includes three shots giving the second at two months and the third at six months after the initial shot. Recently, it has been shown that the use of a two shot scheme (0 and 6 months) is equally effective among girls. The purpose of this study is to determine that the immunogenicity is non-inferior in boys using a two shot scheme compared with young women and girls.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-02
• Status Verified: 2015-03
• Study First Submitted: 2015-03-03
• Study First Submitted QC: 2015-03-06
• Last Update Submitted: 2015-03-06
• Study First Posted: 2015-03-09
• Last Update Posted: 2015-03-09
• Primary Completion: 2015-10
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• All those children whose parents accept their participation in the study.

Exclusion Criteria

• Fever,
• previous vaccination against HPV,
• allergy to vaccine components,
• thrombocytopenia,
• immunosuppression,
• diarrhea,
• vomiting,
• dyscrasia,
• administration of another anti-viral vaccine in the previous 15 days.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Immunogenicity (Geometric mean antibody concentration will be compared between the two groups)	7 months (1 month after the last dose)	Geometric means will be compared between the two groups of interest (boys and young women)

Trial Locations

Locations (1)

Malaquias Lopez Cervantes; 🇲🇽 Mexico, Mexico city, Mexico